A Phase 1/2 interventional study of Opt-IVF and Control in Infertility (IVF Patients), sponsored by Urmila DIwekar. Recruiting at 2 sites in United States. Open to female participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-29.
Sponsored by Urmila DIwekar · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 395 studies in Infertility with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Infertility · United States.
Among the 395 studies in Infertility with a site in United States, this one is the 73rd largest by planned enrollment of the 274 interventional ones that give a count, is one of 21 that started in 2025, is one of 5 in phase 1/2, reaches primary completion later than 16 of the 82 other live ones, and was the 377th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →62 of the 395 studies in Infertility with a site in United States are open now. Recruiting first, the newest first:
Abigail Mancuso · Sites in United States
Ages 18–45
Brigham and Women's Hospital · Sites in United States
Ages 18–40 · Women only · Healthy volunteers
Kevin Doody · Sites in United States
Ages 18–35 · Women only
University of Oklahoma · Sites in United States
Ages 18–45 · Women only
Reproductive Medicine Associates of New Jersey · Sites in United States
Ages 18–42 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 20 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
395 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 32 · Phase 3 31 · Phase 4 35
First in 1989; this study’s year is marked. 21 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 84 across the 274 interventional studies, 150 across the 119 observational. Of the 252 that completed or were terminated, 57 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 395 have an industry lead sponsor. The 10 most frequent:
Urmila DIwekar is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Urmila DIwekar has 2 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
25 of the studies in Infertility with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06375811Phase 3Yale UniversityPre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp | 2027-03-31 |
| NCT06858111Phase 3Gameto, Inc.Fertilo In Vitro Research Study and Trial | 2027-05 |
| NCT04544462Genomic Prediction Inc.ANXA5 M2 Haplotyping in IVF Patients and Embryos | 2026-11 |
| NCT07083700Inception Fertility Research Institute, LLCFrame Support Study | 2026-12 |
| NCT02573415The Cleveland ClinicUterine Transplantation for the Treatment of Uterine Factor Infertility | 2026-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 395 studies in Infertility with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A clinical trial will determine the effectiveness of using the Opt-IVF decision support tool for each patient's personalized and optimal drug dosage profile in the United States.
This will be a two-arm randomized clinical trial involving more than 100 patients; one arm will undergo superovulation using dosages predicted by the decision support tool, while the other will undergo the current standard treatment. The research question is whether outcomes of patient dosage treatment using Opt-IVF are better or similar to the current practice. We will compare the outcomes of the two groups of patients in terms of the numbers and percentage of mature follicles retrieved at the end of each cycle, total FSH and HMG dosages used, and the number of required testing days for that cycle, total number of M2s, Number of embryos, Number of Grade A embryos and Number of Grade A blastocysts.
The trial is for research purposes only. The current tool has not been submitted for any regulatory body approval.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All female patients who will not undergo IVF or whose cycles will be converted to IUI. Male patients will not be enrolled in this study. No donor cycles.
This arm will get dosage prescribed by the doctor
Other: Control
This arm patients will get dosage provided by Opt-IVF
Combination Product: Opt-IVF
Opt-IVF provides optimized dosage profile for each patient
Physicians will decide the dosage for each day for patients
Total Gonadotropin Dosage
Total Gonadotropin Dosage for the cycle
Time frame: Two weeks after the start of the cycle
Total Oocytes Retrieved
Total Oocytes Retrieved
Time frame: Two weeks after the start of the stimulation cycle
M2 Oocytes
Total M2 Oocytes
Time frame: Two weeks after the start of the stimulation cycle
Total Embryos Formed
Total Embryos Formed
Time frame: Two weeks after the start of stimulation cycle
Grade A embryos/Blastocytes
Grade A Day 3 Embryos or Grade A Day 5 Blastocytes
Time frame: Three weeks after the start of stimulation cycle
Pregnancy Rates
Cycle pregnancy rate till the first transfer
Time frame: one month after first transfer
Plan to share: Yes — Data will be available by contacting Dr. Urmila Diwekar
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: After completion of the trial
Access criteria: by contacting Dr. Diwekar
Start is estimated for Sep 2025; primary completion for Feb 2026, 4 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Urmila DIwekar